Glecaprevir Pibrentasvir (Mavyret) prior authorization at Kaiser Permanente
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Kaiser Permanente requires prior-authorization documentation for Glecaprevir Pibrentasvir (Mavyret): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Kaiser Permanente reviews Glecaprevir Pibrentasvir (Mavyret) prior authorizations against its medical policy . Kaiser Permanente-specific context: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Kaiser Permanente's medical policy URL referenced in the cover letter
Kaiser Permanente's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Out-of-network non-emergency denials
- Specialty referrals delayed
- Mental health access (DMHC complaints common)
Glecaprevir Pibrentasvir (Mavyret)-specific denial patterns and context
Across payers (not just Kaiser Permanente), Glecaprevir Pibrentasvir (Mavyret)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Liver fibrosis threshold requirement (now legally indefensible per AASLD-IDSA HCV Guidance)
- Substance-use restrictions / sobriety requirements (HHS and AASLD oppose)
- Specialty pharmacy network restriction
- Prior treatment failure documentation
Brand: Mavyret. Pangenotypic DAA combination (NS3/4A + NS5A inhibitor) for HCV. 8-week regimen for treatment-naive without cirrhosis or with compensated cirrhosis — shortened from 12-week per 2019 FDA label update. Pediatric approval down to age 3.
Manufacturer patient-assistance program: AbbVie Patient Assistance Foundation (Mavyret) — relevant when a Kaiser Permanente denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Kaiser Permanente gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.kaiserpermanente.org) with the same packet plus a peer-reviewed citation supporting Glecaprevir Pibrentasvir (Mavyret)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Kaiser Permanente denial on DenialHelp.
Contact Kaiser Permanente
- Provider portal: https://providers.kaiserpermanente.org
Frequently asked questions
What documentation does Kaiser Permanente need for Glecaprevir Pibrentasvir (Mavyret) prior auth?
Kaiser Permanente's typical PA packet for Glecaprevir Pibrentasvir (Mavyret): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Kaiser Permanente?
Standard Glecaprevir Pibrentasvir (Mavyret) PA decisions at Kaiser Permanente: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Kaiser Permanente most often reject Glecaprevir Pibrentasvir (Mavyret) for?
Across Kaiser Permanente's book the common rejection patterns include: Out-of-network non-emergency denials; Specialty referrals delayed; Mental health access (DMHC complaints common). For Glecaprevir Pibrentasvir (Mavyret) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Kaiser Permanente on Glecaprevir Pibrentasvir (Mavyret)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Glecaprevir Pibrentasvir (Mavyret) PA packet
Open ApprovalHelp — generate a Glecaprevir Pibrentasvir (Mavyret) prior-auth packet tailored to Kaiser Permanente's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com